Literature DB >> 17409978

A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer.

Shirin Shafazand1, Michael K Gould.   

Abstract

INTRODUCTION: Estimating the clinical probability of mediastinal metastasis in patients with non-small cell lung cancer (NSCLC) can facilitate the selection and interpretation of staging tests.
PURPOSE: We sought to identify independent clinical predictors of mediastinal metastasis and to develop a prediction rule to estimate the pretest probability of nodal metastasis in patients with NSCLC.
METHODS: We used data from a randomized controlled trial of selective versus routine mediastinoscopy to develop a clinical prediction model.
RESULTS: Five hundred sixty-six patients were included, with a mean age of 65 +/- 9 years; 31% had positive lymph nodes. Independent predictors of positive nodes included adenocarcinoma or large cell histology (OR 2.6, 95% confidence interval [CI] = 1.8-3.9), apparent metastatic disease on chest radiography (OR 2.4, 95% CI = 1.2-4.7), central location of the primary tumor (OR 2.1, 95% CI = 1.4-3.3), symptoms from the primary tumor (OR 1.6, 95% CI = 1.1-2.4), tumor diameter > or =3.6 cm (OR 1.5, 95% CI = 1.0-2.3), and age less than 65 years (OR 1.5, 95% CI = 1.0-2.2). Model accuracy and calibration were good, with an area under the receiver operating characteristic curve of 0.70 (95% CI = 0.66-0.75) and good agreement between observed and predicted probabilities of mediastinal metastasis.
CONCLUSIONS: Our prediction rule can be used to estimate the pretest probability of mediastinal metastasis in patients with NSCLC. Such estimates can facilitate clinical decision making when selecting and interpreting the results of noninvasive and invasive staging tests.

Entities:  

Mesh:

Year:  2006        PMID: 17409978

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  17 in total

1.  External validation of a prediction model for pathologic N2 among patients with a negative mediastinum by positron emission tomography.

Authors:  Farhood Farjah; Leah M Backhus; Thomas K Varghese; James P Manning; Aaron M Cheng; Michael S Mulligan; Douglas E Wood
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

2.  A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer: HAL.

Authors:  Oisin J O'Connell; Francisco A Almeida; Michael J Simoff; Lonny Yarmus; Ray Lazarus; Benjamin Young; Yu Chen; Roy Semaan; Timothy M Saettele; Joseph Cicenia; Harmeet Bedi; Corrine Kliment; Liang Li; Sonali Sethi; Javier Diaz-Mendoza; David Feller-Kopman; Juhee Song; Thomas Gildea; Hans Lee; Horiana B Grosu; Michael Machuzak; Macarena Rodriguez-Vial; George A Eapen; Carlos A Jimenez; Roberto F Casal; David E Ost
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

3.  Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients.

Authors:  Andrea Bille; Kaitlin M Woo; Usman Ahmad; Nabil P Rizk; David R Jones
Journal:  Eur J Cardiothorac Surg       Date:  2017-04-01       Impact factor: 4.191

4.  Development and validation of a preoperative noninvasive predictive model based on circular tumor DNA for lymph node metastasis in resectable non-small cell lung cancer.

Authors:  Rusi Zhang; Xuewen Zhang; Zirui Huang; Fang Wang; Yongbin Lin; Yingsheng Wen; Li Liu; Jinbo Li; Xinyi Liu; Wenzhuan Xie; Mengli Huang; Gongming Wang; Longjun Yang; Dechang Zhao; Xiangyang Yu; Kexing Xi; Weidong Wang; Ling Cai; Lanjun Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-06

5.  Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer.

Authors:  Gino In; Jeremy Mason; Sonia Lin; Paul K Newton; Peter Kuhn; Jorge Nieva
Journal:  Converg Sci Phys Oncol       Date:  2017-07-13

6.  CT-based radiomics signature for the stratification of N2 disease risk in clinical stage I lung adenocarcinoma.

Authors:  Minglei Yang; Yunlang She; Jiajun Deng; Tingting Wang; Yijiu Ren; Hang Su; Junqi Wu; Xiwen Sun; Gening Jiang; Ke Fei; Lei Zhang; Dong Xie; Chang Chen
Journal:  Transl Lung Cancer Res       Date:  2019-12

7.  Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models.

Authors:  Gabriela Martinez-Zayas; Francisco A Almeida; Lonny Yarmus; Daniel Steinfort; Donald R Lazarus; Michael J Simoff; Timothy Saettele; Septimiu Murgu; Tarek Dammad; D Kevin Duong; Lakshmi Mudambi; Joshua J Filner; Sofia Molina; Carlos Aravena; Jeffrey Thiboutot; Asha Bonney; Adriana M Rueda; Labib G Debiane; D Kyle Hogarth; Harmeet Bedi; Mark Deffebach; Ala-Eddin S Sagar; Joseph Cicenia; Diana H Yu; Avi Cohen; Laura Frye; Horiana B Grosu; Thomas Gildea; David Feller-Kopman; Roberto F Casal; Michael Machuzak; Muhammad H Arain; Sonali Sethi; George A Eapen; Louis Lam; Carlos A Jimenez; Manuel Ribeiro; Laila Z Noor; Atul Mehta; Juhee Song; Humberto Choi; Junsheng Ma; Liang Li; David E Ost
Journal:  Chest       Date:  2021-04-28       Impact factor: 10.262

8.  A Model Predicting Lymph Node Status for Patients with Clinical Stage T1aN0-2M0 Nonsmall Cell Lung Cancer.

Authors:  Ruo-Chuan Zang; Bin Qiu; Shu-Geng Gao; Jie He
Journal:  Chin Med J (Engl)       Date:  2017-02-20       Impact factor: 2.628

9.  Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death.

Authors:  Wenjie Xia; Anpeng Wang; Meng Jin; Qixing Mao; Wenying Xia; Gaochao Dong; Bing Chen; Weidong Ma; Lin Xu; Feng Jiang
Journal:  Cancer Manag Res       Date:  2018-01-08       Impact factor: 3.989

10.  Nomogram to Predict Occult N2 Lymph Nodes Metastases in Patients With Squamous Nonsmall Cell Lung Cancer.

Authors:  Long Jiang; Shanshan Jiang; Yongbin Lin; Han Yang; Zehua Xie; Yaobin Lin; Hao Long
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.